CLINICAL EFFICACY OF DEXAMETHASONE VERSUS HYDROCORTISONE IN ACUTE EXACERBATION OF ASTHMA IN CHILDREN
DOI:
https://doi.org/10.54112/pjicm.v4i02.35Keywords:
Acute Asthma, Dexamethasone, Hydrocortisone, Pediatric, Randomized Controlled TrialAbstract
Background: Asthma is a prevalent chronic respiratory condition among children worldwide, significantly impacting their health, quality of life, and healthcare systems. Acute exacerbations of asthma require prompt and effective management to reduce morbidity. Objective: To compare the clinical efficacy and safety of dexamethasone versus hydrocortisone in children with acute asthma exacerbations. Study Design: Randomized controlled trial. Setting: Emergency Pediatric Medicine Department and General Medical Ward of the Children's Hospital, Lahore. Duration of Study: November 2023 to April 2024. Methods: Children aged 6–15 years presenting with acute asthma exacerbations were enrolled and randomly assigned to receive either dexamethasone or hydrocortisone. Baseline characteristics, including age, gender, weight, respiratory rate, oxygen saturation, asthma history duration, and initial FEV1, were recorded. The primary outcomes assessed included changes in respiratory parameters, duration of respiratory support, and length of hospital stay. Results: The study included 110 participants, with 55 patients in each group. The mean age was 9.5±3.45 years in the dexamethasone group and 9.4±2.91 years in the hydrocortisone group. Both groups showed comparable gender distribution (60% male and 58% male, respectively) and baseline characteristics. The mean respiratory rate was 32±4.2 bpm in the dexamethasone group versus 31±4.1 bpm in the hydrocortisone group, while oxygen saturation was 94±2% versus 93±2.4%, respectively. The mean hospital stay was shorter in the dexamethasone group (3.1±0.9 days) compared to the hydrocortisone group (3.6±1.1 days). Dexamethasone demonstrated faster improvement in respiratory parameters and earlier cessation of respiratory support. Conclusion: Dexamethasone is a more effective and convenient option than hydrocortisone for managing acute asthma exacerbations in children, offering faster clinical improvement and shorter hospital stays.
References
Doymaz S, Ahmed YE, Francois D, Pinto R, Gist R, Steinberg M, Giambruno C. Methylprednisolone, dexamethasone or hydrocortisone for acute severe pediatric asthma: does it matter? J Asthma. 2022 Mar;59(3):590-596. doi: 10.1080/02770903.2020.1870130. Epub 2021 Jan 16. PMID: 33380248.
Roddy MR, Sellers AR, Darville KK, Teppa-Sanchez B, McKinley SD, Martin M, Goldenberg NA, Nakagawa TA, Sochet AA. Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial. Pediatr Pulmonol. 2023 Jun;58(6):1719-1727. doi: 10.1002/ppul.26386. Epub 2023 Mar 17. PMID: 36929864.
Schivo M, Phan C, Louie S, Harper RW. Critical asthma syndrome in the ICU. Clin Rev Allergy Immunol. 2015;48:31-44.
Kelly CS, Andersen CL, Pestian JP, et al. Improved outcomes for hospitalized asthmatic children using a clinical pathway. Ann Allergy Asthma Immunol. 2000;84:509-516.
Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;6:1.
Hoch H, Kattan M, Szefler SJ. Challenges in managing difficult-to-treat asthma in children: stop, look, and listen. Pediatr Pulmonol. 2020;55:791-794.
Cloutier MM, Teach SJ, Lemanske RF, Jr., Blake KV. The 2020 focused updates to the NIH asthma management guidelines: key points for pediatricians. Pediatrics. 2021;147:e2021050286.
Hemani SA, Glover B, Ball S, et al. Dexamethasone versus prednisone in children hospitalized for acute asthma exacerbations. Hospital Pediatr. 2021;11:1263-1272.
Giuliano JS, Jr., Faustino EVS, Li S, Pinto MG, Canarie MF, Carroll CL. Corticosteroid therapy in critically ill pediatric asthmatic patients*. Pediatr Critical Care Med. 2013;14:467-470.
Sellers AR, Roddy MR, Darville KK, Sanchez-Teppa B, McKinley SD, Sochet AA. Dexamethasone for pediatric critical asthma: a multicenter descriptive study. J Intensiv Care Med. 2022;37(11):1520-1527.
Paniagua N, Lopez R, Muñoz N, et al. Randomized trial of dexamethasone versus prednisone for children with acute asthma exacerbations. J Pediatr. 2017;191:190-196.
Parikh K, Hall M, Mittal V, et al. Comparative effectiveness of dexamethasone versus prednisone in children hospitalized with asthma. J Pediatr. 2015;167:639-644.
Elkharwili DA, Ibrahim OM, Elazab GA, Elrifaey SM. Two regimens of dexamethasone versus prednisolone for acute exacerbations in asthmatic Egyptian children. Eur J Hospital Pharmacy. 2020;27:151-156.
Seghezzo S, Arnold DH, Gay JC, Moore PE, Johnson DP. Dexamethasone for inpatient childhood asthma exacerbations is as effective as short-acting corticosteroid treatment. Ann Allergy Asthma Immunol. 2018;120:94-95.
Cronin JJ, McCoy S, Kennedy U, et al. A randomized trial of single-dose oral dexamethasone versus multidose prednisolone for acute exacerbations of asthma in children who attend the emergency department. Ann Emerg Med. 2016;67:593-601.
Abaya R, Jones L, Zorc JJ. Dexamethasone compared to prednisone for the treatment of children with acute asthma exacerbations. Pediatr Emerg Care. 2018;34:53-58.
Doymaz S, Ahmed YE, Francois D, Pinto R, Gist R, Steinberg M, Giambruno C. Methylprednisolone, dexamethasone or hydrocortisone for acute severe pediatric asthma: does it matter?. Journal of Asthma. 2022 Feb 15;59(3):590-6.
Castro‐Rodriguez JA, Pincheira MA, Escobar‐Serna DP, Sossa‐Briceño MP, Rodriguez‐Martinez CE. Adding nebulized corticosteroids to systemic corticosteroids for acute asthma in children: A systematic review with meta‐analysis. Pediatric Pulmonology. 2020 Oct;55(10):2508-17.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 R IMTIAZ, S YAMEEN, A HASSAN, HS RAMZAN, SA NIZAMI, Z AYUB
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.